Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Journal of Cancer Research and Clinical Oncology
Published in: Journal of Cancer Research and Clinical Oncology 5/2024

Open Access 01-05-2024 | Bevacizumab | Review

Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors

Authors: Yan Kang, Huiting Li, Yiping Liu, Zheng Li

Published in: Journal of Cancer Research and Clinical Oncology | Issue 5/2024

Login to get access

Abstract

Vascular endothelial growth factor A (VEGF-A), a highly conserved dimeric glycoprotein, is a key regulatory gene and a marker molecule of angiogenesis. The upregulation of VEGF-A facilitates the process of tumor vascularization, thereby fostering the initiation and progression of malignant neoplasms. Many genes can adjust the angiogenesis of tumors by changing the expression of VEGF-A. In addition, VEGF-A also exhibits immune regulatory properties, which directly or indirectly suppresses the antitumor activity of immune cells. The emergence of VEGF-A-targeted therapy alone or in rational combinations has revolutionized the treatment of various cancers. This review discusses how diverse mechanisms in various tumors regulate VEGF-A expression to promote tumor angiogenesis and the role of VEGF-A in tumor immune microenvironment. The application of drugs targeting VEGF-A in tumor therapy is also summarized including antibody molecule drugs and traditional Chinese medicine.
Literature
Abdi S, Montazeri V, Garjani A et al (2020) Coenzyme Q10 in association with metabolism-related AMPK/PFKFB3 and angiogenic VEGF/VEGFR2 genes in breast cancer patients. Mol Biol Rep 47:2459–2473PubMedCrossRef
Al Kawas H, Saaid I, Jank P et al (2022) How VEGF-A and its splice variants affect breast cancer development - clinical implications. Cell Oncol (dordr) 45:227–239PubMedCrossRef
Alfaro C, Suarez N, Gonzalez A et al (2009) Influence of bevacizumab, sunitinib and sorafenib as single agents or in combination on the inhibitory effects of VEGF on human dendritic cell differentiation from monocytes. Br J Cancer 100:1111–1119PubMedPubMedCentralCrossRef
Atkins MB, Plimack ER, Puzanov I et al (2018) Axitinib in combination with pembrolizumab in patients with advanced renal cell cancer: a non-randomised, open-label, dose-finding, and dose-expansion phase 1b trial. Lancet Oncol 19:405–415PubMedPubMedCentralCrossRef
Bakshi HA, Quinn GA, Nasef MM et al (2022) Crocin inhibits angiogenesis and metastasis in colon cancer via TNF-alpha/NF-kB/VEGF pathways. Cells 11:1502PubMedPubMedCentralCrossRef
Boulias K, Greer EL (2023) Biological roles of adenine methylation in RNA. Nat Rev Genet 24:143–160PubMedCrossRef
Castanhole-Nunes MMU, Tunissiolli NM, Oliveira A et al (2022) MiR-612, miR-637, and miR-874 can regulate VEGFA expression in hepatocellular carcinoma cell lines. Genes (basel) 13:282PubMedCrossRef
Chen C, Wei M, Wang C et al (2020) The histone deacetylase HDAC1 activates HIF1alpha/VEGFA signal pathway in colorectal cancer. Gene 754:144851PubMedCrossRef
Chen QZ, Chen Y, Li X et al (2022) TRIB3 interacts with STAT3 to promote cancer angiogenesis. Curr Med Sci 42:932–940PubMedCrossRef
Chen H, Chen X, Ping Z et al (2023) Ligusticum chuanxiong promotes the angiogenesis of preovulatory follicles (F1–F3) in late-phase laying hens. Poult Sci 102:102430PubMedCrossRef
Clou E, Luque Y (2022) Angiogenesis inhibitors: mechanism of action and nephrotoxicity. Nephrol Ther 18:1–6PubMedCrossRef
Dai J, Zhuang Y, Tang M et al (2020) CircRNA UBAP2 facilitates the progression of colorectal cancer by regulating miR-199a/VEGFA pathway. Eur Rev Med Pharmacol Sci 24:7963–7971PubMed
Dai G, Wang D, Ma S et al (2022) ACSL4 promotes colorectal cancer and is a potential therapeutic target of emodin. Phytomedicine 102:154149PubMedCrossRef
Damato A, Iachetta F, Antonuzzo L et al (2020) Phase II study on first-line treatment of NIVolumab in combination with folfoxiri/bevacizumab in patients with advanced COloRectal cancer RAS or BRAF mutated - NIVACOR trial (GOIRC-03-2018). BMC Cancer 20:822PubMedPubMedCentralCrossRef
de Almeida PE, Mak J, Hernandez G et al (2020) Anti-VEGF treatment enhances CD8(+) T-cell antitumor activity by amplifying hypoxia. Cancer Immunol Res 8:806–818PubMedCrossRef
Deng H, Kan A, Lyu N et al (2020) Dual vascular endothelial growth factor receptor and fibroblast growth factor receptor inhibition elicits antitumor immunity and enhances programmed cell death-1 checkpoint blockade in hepatocellular carcinoma. Liver Cancer 9:338–357PubMedPubMedCentralCrossRef
Elebiyo TC, Rotimi D, Evbuomwan IO et al (2022) Reassessing vascular endothelial growth factor (VEGF) in anti-angiogenic cancer therapy. Cancer Treat Res Commun 32:100620PubMedCrossRef
Ferrara N (2011) From the discovery of vascular endothelial growth factor to the introduction of avastin in clinical trials - an interview with Napoleone Ferrara by Domenico Ribatti. Int J Dev Biol 55:383–388PubMedCrossRef
Fujii T, Hirakata T, Kurozumi S et al (2020) VEGF-A is associated with the degree of TILs and PD-L1 expression in primary breast cancer. In Vivo 34:2641–2646PubMedPubMedCentralCrossRef
Fukumura D, Kloepper J, Amoozgar Z et al (2018) Enhancing cancer immunotherapy using antiangiogenics: opportunities and challenges. Nat Rev Clin Oncol 15:325–340PubMedPubMedCentralCrossRef
Gao S, Hu W, Huang X et al (2020) Circ_0001178 regulates miR-382/VEGFA axis to facilitate hepatocellular carcinoma progression. Cell Signal 72:109621PubMedCrossRef
Garcia J, Hurwitz HI, Sandler AB et al (2020) Bevacizumab (Avastin(R)) in cancer treatment: a review of 15 years of clinical experience and future outlook. Cancer Treat Rev 86:102017PubMedCrossRef
Gavalas NG, Tsiatas M, Tsitsilonis O et al (2012) VEGF directly suppresses activation of T cells from ascites secondary to ovarian cancer via VEGF receptor type 2. Br J Cancer 107:1869–1875PubMedPubMedCentralCrossRef
Grassot J, Gouy M, Perriere G et al (2006) Origin and molecular evolution of receptor tyrosine kinases with immunoglobulin-like domains. Mol Biol Evol 23:1232–1241PubMedCrossRef
Griffioen AW, Damen CA, Martinotti S et al (1996) Endothelial intercellular adhesion molecule-1 expression is suppressed in human malignancies: the role of angiogenic factors. Can Res 56:1111–1117
Guan JH, Cao ZY, Guan B et al (2021) Effect of Babao Dan on angiogenesis of gastric cancer in vitro by regulating VEGFA/VEGFR2 signaling pathway. Transl Cancer Res 10:953–965PubMedPubMedCentralCrossRef
Han H, Lin T, Wang Z et al (2023) RNA-binding motif 4 promotes angiogenesis in HCC by selectively activating VEGF-A expression. Pharmacol Res 187:106593PubMedCrossRef
He L, Feng A, Guo H et al (2022) LRG1 mediated by ATF3 promotes growth and angiogenesis of gastric cancer by regulating the SRC/STAT3/VEGFA pathway. Gastric Cancer 25:527–541PubMedCrossRef
Hu-Lowe DD, Zou HY, Grazzini ML et al (2008) Nonclinical antiangiogenesis and antitumor activities of axitinib (AG-013736), an oral, potent, and selective inhibitor of vascular endothelial growth factor receptor tyrosine kinases 1, 2, 3. Clin Cancer Res 14:7272–7283PubMedCrossRef
Hurwitz H, Fehrenbacher L, Novotny W et al (2004) Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 350:2335–2342PubMedCrossRef
Ishikura N, Sugimoto M, Yorozu K et al (2022) Anti-VEGF antibody triggers the effect of anti-PD-L1 antibody in PD-L1(low) and immune desert-like mouse tumors. Oncol Rep 47(2):1
Jeltsch M, Leppanen VM, Saharinen P et al (2013) Receptor tyrosine kinase-mediated angiogenesis Cold Spring. Harb Perspect Biol 5:a009183
Jiang P, Zhang Y, Cui J et al (2022) Inhibitory effects of icotinib combined with antiangiogenic drugs in human non-small cell lung cancer xenograft models are better than single target drugs. Thorac Cancer 13:257–264PubMedCrossRef
Jin Y, Cao J, Hu X et al (2021) Long noncoding RNA TUG1 upregulates VEGFA to enhance malignant behaviors in stomach adenocarcinoma by sponging miR-29c-3p. J Clin Lab Anal 35:e24106PubMedPubMedCentralCrossRef
Kajal K, Bose S, Panda AK et al (2021) Transcriptional regulation of VEGFA expression in T-regulatory cells from breast cancer patients. Cancer Immunol Immunother 70:1877–1891PubMedPubMedCentralCrossRef
Kim KJ, Li B, Winer J et al (1993) Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumour growth in vivo. Nature 362:841–844PubMedCrossRef
Koizumi K, Shintani T, Hayashido Y et al (2022) VEGF-A promotes the motility of human melanoma cells through the VEGFR1-PI3K/Akt signaling pathway In Vitro. Cell Dev Biol Anim 58:758–770CrossRef
Krupitskaya Y, Wakelee HA (2009) Ramucirumab, a fully human mAb to the transmembrane signaling tyrosine kinase VEGFR-2 for the potential treatment of cancer. Curr Opin Investig Drugs 10:597–605PubMed
Lanitis E, Kosti P, Ronet C et al (2021) VEGFR-2 redirected CAR-T cells are functionally impaired by soluble VEGF-A competition for receptor binding. J Immunother Cancer 9:e002151PubMedPubMedCentralCrossRef
Le X, Nilsson MB, Robichaux JP et al (2021) ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC. Cancer Cell 39:1178–1180PubMedCrossRef
Leung DW, Cachianes G, Kuang WJ et al (1989) Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 246:1306–1309PubMedCrossRef
Li AM, Boichard A, Kurzrock R (2020a) Mutated TP53 is a marker of increased VEGF expression: analysis of 7525 pan-cancer tissues. Cancer Biol Ther 21:95–100PubMedCrossRef
Li W, Xu Y, Wang X et al (2020b) circCCT3 modulates vascular endothelial growth factor A and Wnt signaling to enhance colorectal cancer metastasis through sponging miR-613. DNA Cell Biol 39:118–125PubMedCrossRef
Li J, Li XL, Li CQ (2023) Immunoregulation mechanism of VEGF signaling pathway inhibitors and its efficacy on the kidney. Am J Med Sci 366:404–412PubMedCrossRef
Liu M, Xu W, Su M et al (2020) REC8 suppresses tumor angiogenesis by inhibition of NF-kappaB-mediated vascular endothelial growth factor expression in gastric cancer cells. Biol Res 53:41PubMedPubMedCentralCrossRef
Liu X, He H, Zhang F et al (2022a) m6A methylated EphA2 and VEGFA through IGF2BP2/3 regulation promotes vasculogenic mimicry in colorectal cancer via PI3K/AKT and ERK1/2 signaling. Cell Death Dis 13:483PubMedPubMedCentralCrossRef
Liu Z, Liu X, Li F et al (2022b) Overexpression of hypoxia-inducible factor 1alpha and excessive vascularization in the peri-implantation endometrium of infertile women with chronic endometritis. Front Endocrinol (lausanne) 13:1001437PubMedCrossRef
Lu X, Zhou B, Cao M et al (2021) CTEN inhibits tumor angiogenesis and growth by targeting VEGFA through down-regulation of beta-catenin in breast cancer. Technol Cancer Res Treat 20:15330338211045506PubMedPubMedCentralCrossRef
Mielcarska S, Stopinska K, Dawidowicz M et al (2021) GDF-15 level correlates with CMKLR1 and VEGF-A in tumor-free margin in colorectal cancer. Curr Med Sci 41:522–528PubMedCrossRef
Mousa H, Yuan M, Zhang X et al (2020) MicroRNA-4316 inhibits gastric cancer proliferation and migration via directly targeting VEGF-A. Cancer Cell Int 20:62PubMedPubMedCentralCrossRef
Nakai H, Matsumura N (2022) The roles and limitations of bevacizumab in the treatment of ovarian cancer. Int J Clin Oncol 27:1120–1126PubMedCrossRef
Nayak D, Paul S, Das C et al (2023) Quinacrine and Curcumin in combination decreased the breast cancer angiogenesis by modulating ABCG2 via VEGF A. J Cell Commun Signal 17:609–626PubMedCrossRef
Nefedova Y, Huang M, Kusmartsev S et al (2004) Hyperactivation of STAT3 is involved in abnormal differentiation of dendritic cells in cancer. J Immunol 172:464–474PubMedCrossRef
Niu X, Wei N, Peng L et al (2022) miR-34a-5p plays an inhibitory role in hepatocellular carcinoma by regulating target gene VEGFA. Malays J Pathol 44:39–52PubMed
Qian XL, Xu P, Zhang YQ et al (2020) Increased number of intratumoral IL-17+ cells, a harbinger of the adverse prognosis of triple-negative breast cancer. Breast Cancer Res Treat 180:311–319PubMedCrossRef
Reck M, Mok TSK, Nishio M et al (2019) Atezolizumab plus bevacizumab and chemotherapy in non-small-cell lung cancer (IMpower150): key subgroup analyses of patients with mutations or baseline liver metastases in a randomised, open-label phase 3 trial. Lancet Respir Med 7:387–401PubMedCrossRef
Rehman S, Ullah H, Nagarajan JS et al (2022) Pneumothorax as a complication of bevacizumab-containing chemotherapy: a systematic review of case reports. Cureus 14:e27338PubMedPubMedCentral
Sim WK, Park JH, Kim KY et al (2020) Robustaflavone induces G0/G1 cell cycle arrest and apoptosis in human umbilical vein endothelial cells and exhibits anti-angiogenic effects in vivo. Sci Rep 10:11070PubMedPubMedCentralCrossRef
Situ Y, Lu X, Cui Y et al (2022) Systematic analysis of CXC chemokine-vascular endothelial growth factor A network in colonic adenocarcinoma from the perspective of angiogenesis. Biomed Res Int 2022:5137301PubMedPubMedCentralCrossRef
Sternberg CN, Davis ID, Mardiak J et al (2010) Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial. J Clin Oncol 28:1061–1068PubMedCrossRef
Strawn LM, McMahon G, App H et al (1996) Flk-1 as a target for tumor growth inhibition. Can Res 56:3540–3545
Strumberg D (2005) Preclinical and clinical development of the oral multikinase inhibitor sorafenib in cancer treatment. Drugs Today (barc) 41:773–784PubMedCrossRef
Sufianov A, Begliarzade S, Kudriashov V et al (2023) Role of miRNAs in vascular development. Noncoding RNA Res 8:1–7PubMedCrossRef
Sugawara S, Lee JS, Kang JH et al (2021) Nivolumab with carboplatin, paclitaxel, and bevacizumab for first-line treatment of advanced nonsquamous non-small-cell lung cancer. Ann Oncol 32:1137–1147PubMedCrossRef
Sun DS, Guan CH, Wang WN et al (2021) LncRNA NORAD promotes proliferation, migration and angiogenesis of hepatocellular carcinoma cells through targeting miR-211–5p/FOXD1/VEGF-A axis. Microvasc Res 134:104120PubMedCrossRef
Tamura R, Morimoto Y, Sato M et al (2020) A pilot study of the adverse events caused by the combined use of bevacizumab and vascular endothelial growth factor receptor-targeted vaccination for patients with a malignant glioma. Vaccines (basel) 8:498PubMedCrossRef
Tanaka I, Morise M, Miyazawa A et al (2020) Potential benefits of bevacizumab combined with platinum-based chemotherapy in advanced non-small-cell lung cancer patients with EGFR mutation. Clin Lung Cancer 21(273–80):e4
Tang L, Wang S, Wang Y et al (2023) LncRNA-UCA1 regulates lung adenocarcinoma progression through competitive binding to miR-383. Cell Cycle 22:213–228PubMedCrossRef
Tian M, Chen K, Huang J et al (2021) Asiatic acid inhibits angiogenesis and vascular permeability through the VEGF/VEGFR2 signaling pathway to inhibit the growth and metastasis of breast cancer in mice. Phytother Res 35:6389–6400PubMedCrossRef
Van Cutsem E, Paccard C, Chiron M et al (2020) Impact of prior bevacizumab treatment on VEGF-A and PlGF levels and outcome following second-line aflibercept treatment: biomarker post hoc analysis of the VELOUR trial. Clin Cancer Res 26:717–725PubMedCrossRef
Wang D, Sun H, Wei J et al (2017) CXCL1 Is Critical for Premetastatic Niche Formation and Metastasis in Colorectal Cancer. Can Res 77:3655–3665CrossRef
Wang B, Duan R, Li ZB et al (2020a) Circ-RPL15/miR-146b-3p/VEGFA feedback loop is responsible for triggering proliferation and migration in glioma. Eur Rev Med Pharmacol Sci 24:6204–6210PubMed
Wang M, Zeng Q, Li Y et al (2020b) Bevacizumab combined with apatinib enhances antitumor and anti-angiogenesis effects in a lung cancer model in vitro and in vivo. J Drug Target 28:961–969PubMedCrossRef
Wang K, Wang B, Wang Z et al (2021a) Alginic acid inhibits non-small cell lung cancer-induced angiogenesis via activating miR-506 expression. J Nat Med 75:553–564PubMedCrossRef
Wang L, Zhao L, Zhang L et al (2021b) Vascular endothelial growth factor promotes cancer stemness of triple-negative breast cancer via MAPK/ERK pathway. Nan Fang Yi Ke Da Xue Xue Bao 41:1484–1491PubMed
Wang L, Xie Y, Wang J et al (2022) Characterization of a novel LUCAT1/miR-4316/VEGF-A axis in metastasis and glycolysis of lung adenocarcinoma. Front Cell Dev Biol 10:833579PubMedPubMedCentralCrossRef
Watari K, Shibata T, Fujita H et al (2020) NDRG1 activates VEGF-A-induced angiogenesis through PLCgamma1/ERK signaling in mouse vascular endothelial cells. Commun Biol 3:107PubMedPubMedCentralCrossRef
Wei L, Sun C, Zhang Y et al (2022) miR-503-5p inhibits colon cancer tumorigenesis, angiogenesis, and lymphangiogenesis by directly downregulating VEGF-A. Gene Ther 29:28–40PubMedCrossRef
Wilhelm SM, Carter C, Tang L et al (2004) BAY 43–9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Can Res 64:7099–7109CrossRef
Wu H, Wei M, Jiang X et al (2020) lncRNA PVT1 promotes tumorigenesis of colorectal cancer by stabilizing miR-16-5p and interacting with the VEGFA/VEGFR1/AKT Axis. Mol Ther Nucleic Acids 20:438–450PubMedPubMedCentralCrossRef
Wu SX, Ye SS, Hong YX et al (2022) Hepatitis B virus small envelope protein promotes hepatocellular carcinoma angiogenesis via endoplasmic reticulum stress signaling to upregulate the expression of vascular endothelial growth factor A. J Virol 96:e0197521PubMedCrossRef
Xia Z, Xiao J, Dai Z et al (2022) Membrane progesterone receptor alpha (mPRalpha) enhances hypoxia-induced vascular endothelial growth factor secretion and angiogenesis in lung adenocarcinoma through STAT3 signaling. J Transl Med 20:72PubMedPubMedCentralCrossRef
Xie H, Lafky JM, Morlan BW et al (2020) Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance). Ther Adv Med Oncol 12:175883592091091CrossRef
Xu Y, Wang C, Chen X et al (2020) San huang decoction targets aurora kinase a to inhibit tumor angiogenesis in breast cancer. Integr Cancer Ther 19:1534735420983463PubMedPubMedCentralCrossRef
Yang Z, Wang T, Wu D et al (2020) RNA N6-methyladenosine reader IGF2BP3 regulates cell cycle and angiogenesis in colon cancer. J Exp Clin Cancer Res 39:203PubMedPubMedCentralCrossRef
Ye J, Zhu J, Chen H et al (2020) A novel lncRNA-LINC01116 regulates tumorigenesis of glioma by targeting VEGFA. Int J Cancer 146:248–261PubMedCrossRef
Zhang Q, Lei L, Jing D (2020a) Knockdown of SERPINE1 reverses resistance of triple-negative breast cancer to paclitaxel via suppression of VEGFA. Oncol Rep 44:1875–1884PubMedPubMedCentral
Zhang S, Zhang R, Xu R et al (2020b) MicroRNA-574-5p in gastric cancer cells promotes angiogenesis by targeting protein tyrosine phosphatase non-receptor type 3 (PTPN3). Gene 733:144383PubMedCrossRef
Zhang X, Zou G, Li X et al (2020c) An isoflavone derivative potently inhibits the angiogenesis and progression of triple-negative breast cancer by targeting the MTA2/SerRS/VEGFA pathway. Cancer Biol Med 17:693–706PubMedPubMedCentralCrossRef
Zhang YY, Sun JY, Qi Y et al (2020d) Long non-coding RNA TPT1-AS1 promotes angiogenesis and metastasis of colorectal cancer through TPT1-AS1/NF90/VEGFA signaling pathway. Aging-Us 12:6191–6205CrossRef
Zhang J, Zhang J, Pang X et al (2021) MiR-205-5p suppresses angiogenesis in gastric cancer by downregulating the expression of VEGFA and FGF1. Exp Cell Res 404:112579PubMedCrossRef
Zhang G, Wang T, Huang Z et al (2022) METTL3 dual regulation of the stability of LINC00662 and VEGFA RNAs promotes colorectal cancer angiogenesis. Discov Oncol 13:89PubMedPubMedCentralCrossRef
Zhang H, Zhou J, Li J et al (2023) N6-methyladenosine promotes translation of VEGFA to accelerate angiogenesis in lung cancer. Cancer Res 83:2208–2225PubMedCrossRef
Zheng X, Ma YF, Zhang XR et al (2020) Circ_0056618 promoted cell proliferation, migration and angiogenesis through sponging with miR-206 and upregulating CXCR4 and VEGF-A in colorectal cancer. Eur Rev Med Pharmacol Sci 24:4190–4202PubMed
Zou G, Zhang X, Wang L et al (2020) Herb-sourced emodin inhibits angiogenesis of breast cancer by targeting VEGFA transcription. Theranostics 10:6839–6853PubMedPubMedCentralCrossRef
Metadata
Title
Regulation of VEGF-A expression and VEGF-A-targeted therapy in malignant tumors
Authors
Yan Kang
Huiting Li
Yiping Liu
Zheng Li
Publication date
01-05-2024
Publisher
Springer Berlin Heidelberg
Published in
Journal of Cancer Research and Clinical Oncology / Issue 5/2024
Print ISSN: 0171-5216
Electronic ISSN: 1432-1335
DOI
https://doi.org/10.1007/s00432-024-05714-5

Other articles of this Issue 5/2024

Journal of Cancer Research and Clinical Oncology 5/2024 Go to the issue

Research

Tumor infiltrating B lymphocytes (TIBs) associate with poor clinical outcomes, unfavorable therapeutic benefit and immunosuppressive context in metastatic clear cell renal cell carcinoma (mccRCC) patients treated with anti-PD-1 antibody plus Axitinib

Research

Safety, efficacy, and survival of different transarterial chemoembolization techniques in the management of unresectable hepatocellular carcinoma: a comparative single-center analysis

Research

The clinical practice and dosimetric outcome of the manual adaptive planning during definitive radiotherapy for cervical cancer

Research

Evaluating the effects of various ethanolic medicinal plant extracts on metastatic breast cancer proliferation, invasion, and expression of a novel potential drug target; CD82 metastatic suppressor protein, and on in vivo angiogenesis using the ex ovo yolk sac membrane (YSM) assay

Research

Endoscopic submucosal dissection versus surgery for T1b esophageal carcinoma: a single-center retrospective study

Research

GALAD score as a prognostic model for recurrence of hepatocellular carcinoma after local ablation
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine
Image Credits